To see the complete index of our coverage for this conference, click here.
Although the risk of heart attack in people with HIV remains low, it is important to consider all aspects of health care for HIV-infected individuals, including modification of traditional heart disease risk factors. Dr. Judy Aberg reports.
It appears that nevirapine once daily or twice daily is similar to efavirenz in naive patients. Dr. Andy Pavia covers one of the most eagerly awaited studies of the Retrovirus conference.
Tipranavir is a protease inhibitor (PI) in the final stages of clinical testing. It has been touted as having activity against multi-PI resistant strains of virus and is being studied as a twice-daily-administered drug. Dr. David Wohl reports.
Doctors and HIVers alike can't stop gushing about tenofovir (Viread), which seems to work wonderfully in almost any situation. Dr. David Wohl takes a look at the latest research on tenofovir -- a 96-week study comparing it to d4T.
Results from one study position a new pro-drug of Agenerase, GW433908, as a first-line protease inhibitor treatment. Dr. Keith Henry reports.
With the results of a recent study it is clear that the formal indication for the use of TDF and ddI co-administration is reducing the dose of ddI EC to 250 mg. Dr. Edwin DeJesus reports.
Although up to 11 percent of newly infected patients in a recent regional study showed resistance to different drug classes, it imperfectly predicted treatment response. Dr. Jonathan Schapiro reports.
Coverage Provided By:
The 10th Conference on Retroviruses and Opportunistic Infections drew more than 3,200 clinicians and
basic scientists from around the world to present the latest research on
HIV, AIDS, and opportunistic infections. The meeting was sponsored by
the Foundation for Retrovirology and Human Health and is in scientific
collaboration with the National Institute of Allergy and Infectious
Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC).
This conference, regarded as one of the most important scientific
gatherings of the year, was created to provide a forum for scientists and
clinicians to present, discuss, and critique developments in the field of
human retrovirology and related opportunistic complications.
For a PDF of the program, click here. Also check out the webcasts of the conference's oral sessions, which include audio, video and slides.
Funding for coverage of this conference is provided, in part, by unrestricted educational grants from Boehringer Ingelheim Pharmaceuticals, Gilead Sciences and GlaxoSmithKline.
All coverage is © 2003 Body Health Resources Corporation.